All News

Camrelizumab and rivoceranib appear to be an appropriate novel, first-line regimen for unresectable hepatocellular carcinoma.

Sandra P. D’Angelo, MD, reviews current treatments in sarcoma, and how she interacts with her multidisciplinary counterparts to offer the best care to her patients.

JZP458 is part of a multi-agent chemotherapy regimen for lymphoblastic lymphoma and acute lymphoblastic leukemia, and can be used for adult and pediatric patients.

Key points from a discussion of the role of bispecific antibodies in the treatment of multiple myeloma.

According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Key points from a discussion of the clinical data behind both BCMA- and non–BCMA-targeting bispecifics in multiple myeloma.

Investigators will submit data from the phase 3 ENHANCE trial evaluating magrolimab plus azacitidine in higher-risk myelodysplastic syndromes for presentation at a future medical meeting.

Data from the phase 3 PRIME trial show improved survival outcomes with frontline niraparib maintenance therapy among patients with advanced ovarian cancer.

Experts review treatment options for acute graft-versus-host disease and discuss data from post hoc analyses of the REACH2 trial.

Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.

The European Commission will evaluate elacestrant in locally advanced or metastatic breast cancer after receiving a positive opinion on approval from the CHMP.

Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.

Thoracic radiotherapy appears to be tolerable and effective in a real-world cohort of patients with extensive-stage small-cell lung cancer.

Findings from the phase 3 KEYNOTE-811 trial support the CHMP’s recommendation to approve pembrolizumab plus trastuzumab in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Data from a phase 1b dose escalation and expansion study highlight an encouraging duration of remission using APVO436 plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Data from the phase 3 QuANTUM-First trial support the FDA’s approval of quizartinib for managing FLT3-ITD–positive acute myeloid leukemia.

The safety profile of pembrolizumab among patients with high-risk locally advanced cervical cancer in the phase 3 KEYNOTE-A18 trial appears to be consistent with previous reports of the agent.

Umbralisib in combination with ublituximab and venetoclax appears tolerable and yields responses in a small cohort of patients with mantle cell lymphoma.

The investigational antibody-drug conjugate ARX517 is currently under evaluation in patients with metastatic castration-resistant prostate cancer as part of the phase 1/2 APEX-01 trial.

Findings from the REBECCA trial support additional research for nurse navigation intervention for managing psychological vulnerability among patients with breast cancer.

Findings from a phase 2 study may inform the design of future trials assessing fecal microbiota transplants in patients with acute myeloid leukemia.

Selinexor plus ruxolitinib is under investigation as a treatment for JAK inhibitor-naïve patients with myelofibrosis as part of the phase 3 XPORT-MF-034 trial.

The addition of stereotactic radiotherapy to immune checkpoint inhibition appears safe but yields no significant survival benefit among patients with advanced solid tumors.

A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Eltrombopag may be an effective therapy for the ‘challenging condition’ of severe thrombocytopenia in patients with low-risk myelodysplastic syndromes.

Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.

The new drug application for rivoceranib plus camrelizumab in unresectable hepatocellular carcinoma is supported by findings from the phase 3 CARES 310 study.

Investigators report a disparity in survival among Black patients with inflammatory breast cancer, although receipt of treatment does not appear to vary according to race.

Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.